Low donor T-cell chimerism
Showing 1 - 25 of >10,000
Graft-versus-host Disease, Poor Graft Function, Low Donor T-cell Chimerism Trial in Belgium, Netherlands (Mesenchymal stem
Recruiting
- Graft-versus-host Disease
- +2 more
- Mesenchymal stem cells
-
Edeghem, Antwerpen, Belgium
- +11 more
Sep 19, 2022
Predict T Cell Chimerism After MSD SCT for SCD?
Recruiting
- Sickle Cell Disease
- Alemtuzumab Injection [Campath]
-
Amsterdam, NetherlandsAmsterdam Medical Centre
Jun 20, 2023
Myeloid Chimerism Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (CliniMACS CD34 Reagent)
Recruiting
- Myeloid Chimerism
- CliniMACS CD34 Reagent
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Apr 7, 2022
Response Rate Trial in Shanghai (Decitabine)
Completed
- Response Rate
-
Shanghai, Shanghai, ChinaBlood & Marrow Transplantation Center, RuiJin Hospital
May 19, 2021
Hematopoietic Organs; Disorder Trial in Hong Kong (CD62L depleted donor lymphocyte infusion)
Recruiting
- Hematopoietic Organs; Disorder
- CD62L depleted donor lymphocyte infusion
-
Hong Kong, Hong KongHong Kong Children's Hospital
Sep 6, 2023
Living Donor Kidney Transplantation Trial in Palo Alto, Chicago (Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs)
Recruiting
- Living Donor Kidney Transplantation
- Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs
-
Palo Alto, California
- +1 more
May 6, 2022
Cell-Free Nucleic Acids Trial (Cell free DNA analysis)
Not yet recruiting
- Cell-Free Nucleic Acids
- Cell free DNA analysis
- (no location specified)
Jan 27, 2022
Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders Trial in Bethesda,
Recruiting
- Lymphoproliferative Disorders
- +4 more
- Immunosuppression Only Conditioning
- +3 more
-
Bethesda, Maryland
- +1 more
Jan 25, 2023
Sickle Cell Disease Trial in Memphis (hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and
Recruiting
- Sickle Cell Disease
- hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus
- hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus
-
Memphis, TennesseeSt. Jude Children's Research Hospital
May 5, 2022
Intestinal Transplantation Trial in New York (Cell Therapy)
Recruiting
- Intestinal Transplantation
- Cell Therapy
-
New York, New YorkColumbia University Irving Medical Center/NYP
Dec 28, 2021
T Lymphoblastic Leukemia/Lymphoma Trial in Hangzhou (Chidamide)
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
-
Hangzhou, Zhejiang, ChinaThe First Hospital of Zhejiang Medical Colleage Zhejiang Univers
Aug 7, 2023
Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute Trial in Boston (radiation, drug, biological,
Recruiting
- Stem Cell Transplant Complications
- +4 more
- Radiation
- +7 more
-
Boston, MassachusettsDana Farber Cancer Institute
Jan 19, 2023
Multiple Myeloma Trial in New York (drug, biological, procedure)
Active, not recruiting
- Multiple Myeloma
- busulfan
- +4 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jan 3, 2023
T-Cell Acute Lymphoblastic Leukemia/Lymphoma Trial in Beijing (CD5 CAR T (CT125B))
Recruiting
- T-Cell Acute Lymphoblastic Leukemia/Lymphoma
- CD5 CAR T (CT125B)
-
Beijing, Beijing, ChinaBeijing Gaobo Boren Hospital
Aug 3, 2022
Haematological Malignancies Trial in London, Manchester (CD25/71 allodepleted donor T-cells)
Completed
- Haematological Malignancies
- CD25/71 allodepleted donor T-cells
-
London, United Kingdom
- +1 more
Jul 18, 2022
ESRD Trial in Stanford, Madison (Immune Tolerance)
Active, not recruiting
- ESRD
- Immune Tolerance
-
Stanford, California
- +1 more
Jun 30, 2022
Sickle Cell Disease, Sickle Cell Disorder, Hemoglobinopathies Trial in Duarte (Cyclophosphamide, Pentostatin, Rabbit
Recruiting
- Sickle Cell Disease
- +4 more
- Cyclophosphamide
- +5 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jul 6, 2022
Lymphoid Leukemia Trial in Palo Alto (Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector
Not yet recruiting
- Lymphoid Leukemia
- Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)
- Treg CD34+ HSPC (Orca-T)
-
Palo Alto, CaliforniaStanford Cancer Center
Aug 17, 2022
NSCLC Trial (KB-GDT-01)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- KB-GDT-01
- (no location specified)
Sep 29, 2023
T-cell Leukemia/Lymphoma, Refractory T Lymphoblastic Leukemia/Lymphoma, Relapse/Recurrence Trial in Beijing (chimeric antigen
Recruiting
- T-cell Leukemia/Lymphoma
- +2 more
- chimeric antigen receptor T cell treatment
-
Beijing, Beijing, ChinaBeijing Boren Hospital
Jul 31, 2022
Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia Trial in
Suspended
- Juvenile Myelomonocytic Leukemia
- +27 more
- CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 11, 2023
Allogeneic Stem Cell Transplant, Viral Infection, Viral Reactivation Trial in Cincinnati (Viral specific VST Infusion)
Recruiting
- Allogeneic Stem Cell Transplant
- +2 more
- Viral specific VST Infusion
-
Cincinnati, OhioCincinnati Children's Hospital Medical Center
Aug 15, 2022
Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute
Recruiting
- Acute Rejection of Renal Transplant
- Graft Failure
- Donor-derived cell-free DNA
-
Loma Linda, CaliforniaLoma Linda University Health
Jul 19, 2022
Leukemia, Myeloid, Acute Trial in United States (VCAR33)
Not yet recruiting
- Leukemia, Myeloid, Acute
- VCAR33
-
La Jolla, California
- +9 more
Aug 14, 2023
Islet Transplantation Trial in Palo Alto (Infusion of recipient T regulatory cell, Infusion of concomitant Donor Derived
Not yet recruiting
- Islet Transplantation
- Infusion of recipient T regulatory cell
- Infusion of concomitant Donor Derived Vertebral Bone Marrow
-
Palo Alto, CaliforniaStanford University
Jul 25, 2023